Grace Therapeutics, Inc GRCE

Healthcare Biotechnology

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by Joseph_Kon Apr 24, 2018 2:06pm

151 Views

Post# 27933312

RE:$10 MILLION

studduck wrote: At $1.05?? Not a good deal for us bagholders!!

But a fantastic deal for management or whomever is entering it today!

I'm looking forward to results that will crank it up again, November style.

Sell in anger, I benefit. Double down, I benefit. I'm so glad I was patient with this one.

Bullboard Posts

3 Mid-Sized Stocks to Consider This Season